Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Poloxamer 407 is a hydrophilic non-ionic surfactant and triblock copolymer composed of a central hydrophobic block of polypropylene glycol flanked by two hydrophilic polyethylene glycol blocks. It is primarily used as an excipient in pharmaceutical formulations for its surfactant, emulsifying, solubilizing, dispersing, and absorbance-enhancing properties. Poloxamer 407 exhibits thermoreversible gelation—remaining fluid at room temperature but forming a gel at body temperature—which makes it valuable for controlled drug delivery applications across oral, rectal, topical, ophthalmic, nasal and injectable preparations. It is also widely used in cosmetics (e.g., contact lens solutions), mouthwashes and bioprinting due to its unique phase-change properties. While generally considered pharmacologically inactive as an excipient (not acting on specific biological targets), research has explored its potential effects on lipid profiles and renal function when administered parenterally[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on poloxamer 407.